Last updated: February 25, 2026
What is the drug associated with NDC 00093-7386?
NDC 00093-7386 corresponds to Xolair (omalizumab), a monoclonal antibody indicated for allergic asthma, chronic idiopathic urticaria, and other allergy-related conditions. It is marketed by Genentech/Roche.
Market Overview
Therapeutic Area and Indications
- Primarily used for allergic asthma unresponsive to standard therapy.
- Approved for chronic idiopathic urticaria in adult and adolescent populations.
- Off-label applications include nasal polyps and potentially other IgE-mediated conditions.
Size of the Addressable Market
- Global allergy immunotherapy market estimated at $10 billion in 2022.
- U.S. allergen immunotherapy estimated at $4 billion.
- Estimated number of eligible patients in the U.S.: approximately 7 million with moderate to severe allergic asthma or chronic idiopathic urticaria.
Competitive Position
- Xolair faces competition from drugs like Dupixent (dupilumab) and Cinqair (reslizumab).
- Patents protection until 2029-2030, with some biosimilar development underway.
Market Trends
- Increasing prevalence of allergies and asthma.
- Growing awareness and diagnosis rates.
- Expansion of approved indications, broadening the patient base.
- Biosimilar development could impact pricing and market share post-2030.
Pricing and Cost Analysis
Current Pricing Structure
- U.S. list price: Approximately $6,000 to $7,000 per injection.
- Treatment usually involves monthly injections, totaling 6-12 doses per year depending on condition and response.
- Estimated annual cost per patient ranges from $36,000 to $84,000.
Reimbursement & Payer Coverage
- High reimbursement rates in commercial and Medicare populations.
- Payer coverage policies increasingly favor biologics, benefitting market penetration.
Price Trends
- List prices have increased approximately 3-5% annually over the past five years.
- Impacted by inflation, production costs, and regulatory changes.
Future Price Projections (2023–2028)
| Year |
Estimated Average Price per Dose |
Estimated Annual Cost per Patient |
Notes |
| 2023 |
$6,500 |
$78,000 |
Current market rate |
| 2024 |
$6,725 |
$80,700 |
Slight increase due to inflation |
| 2025 |
$6,950 |
$83,400 |
Continued inflation adjustments |
| 2026 |
$7,150 |
$85,800 |
Potential pricing pressure from biosimilars |
| 2027 |
$7,350 |
$88,200 |
Biosimilar competition limits increases |
| 2028 |
$7,500 |
$90,000 |
Market stabilization expected |
Note: These projections assume no major policy or patent changes affecting prices.
Regulatory and Patent Outlook
- Patent exclusivity expected to expire around 2029.
- Biosimilar entry likely by 2028-2030, potentially reducing prices by 25-50% over subsequent years.
- Accelerated approval pathways may influence market dynamics.
Market Entry Barriers and Risks
- High development costs for biosimilars.
- Patent litigation delaying biosimilar launches.
- Payer resistance to high-cost biologics.
- Potential for new therapies to replace or diminish Xolair’s market share.
Key Takeaways
- The U.S. market for Xolair is valued over $3 billion annually.
- Treatment costs are driven by list prices of around $6,000-$7,000 per injection, with annual costs up to $90,000.
- Market growth is supported by increasing allergy prevalence and expanding indications.
- Price trajectories indicate modest increases driven by inflation until biosimilar competition materializes post-2028.
- Patent expirations around 2029-2030 pose significant future pricing and market share risks.
FAQs
Q1: When does patent protection for Xolair expire?
A1: Expected around 2029, after which biosimilars could enter the market.
Q2: How many patients are eligible for Xolair in the U.S.?
A2: Approximately 7 million individuals with moderate to severe allergic asthma or chronic idiopathic urticaria.
Q3: What factors could reduce Xolair’s price before patent expiry?
A3: Biosimilar competition, payer negotiations, regulatory cost pressures.
Q4: What are the key competitors to Xolair?
A4: Dupixent (dupilumab), Cinqair (reslizumab), and potentially next-generation allergy biologics.
Q5: How will biosimilar entry impact market prices?
A5: Likely to decrease prices by 25-50%, similar to trends seen with other biologics.
References
- Capital IQ. (2022). Roche Xolair (omalizumab) market data.
- IQVIA. (2022). Global allergy immunotherapy market report.
- FDA. (2022). Approved indications for omalizumab.
- Medicare & Medicaid Services. (2022). Reimbursement policy for biologics.
- EvaluatePharma. (2022). Biologics market outlook.
